Program

Program Monday, June 2, 2014

7:15 AM - 8:15 AM
EDUCATIONAL SYMPOSIA - CANCELED
7:15 AM - 8:15 AM
Room: Room 518abc (5th Floor)
BUILDING, EMBEDDING, AND OPTIMISING MARKET ACCESS – FROM TECHNICAL EXCELLENCE TO HEARTS AND MINDS IN BOTH ESTABLISHED AND EMERGING MARKETS - CANCELED

(Sponsored by GalbraithWight)

8:30 AM - 2:15 PM
RESEARCH POSTER PRESENTATIONS - SESSION I
8:30 AM - 10:30 AM
WELCOME & FIRST PLENARY SESSION
8:30 AM - 8:40 AM
WELCOME & PRESIDENTIAL ADDRESS
William H. Crown, PhD bio
2013-2014 ISPOR President and Chief Scientific Officer, Optum Labs, Cambridge, MA, USA
8:40 AM - 8:50 AM
MEETING PROGRAM OVERVIEW
Leslie Levin, FRCP(Lon), FRCPC bio
Program Committee Co-Chair, Chief Scientific Officer, MaRS EXCITE, Vice President, Evidence Development and Standards, Health Quality Ontario, and Professor of Medicine, University of Toronto, Toronto, ON, Canada
Don Husereau, MSc, BScPharm bio
Program Committee Co-Chair, Senior Associate, Institute of Health Economics, Adjunct Professor, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
8:50 AM - 8:55 AM
ISPOR 2014 AVEDIS DONABEDIAN OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARD
Announced by: Mark J. Sculpher, MSc, PhD, Chair, ISPOR Avedis Donabedian Lifetime Achievement Award in Health Outcomes Committee and Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
AWARDEE: Bengt Jönsson, PhD bio
Professor of Health Economics, Stockholm School of Economics, Centre for Health Economics, Stockholm, Sweden
8:55 AM - 9:00 AM
2014 ISPOR MARILYN DIX SMITH LEADERSHIP AWARD
Presented by: Scott D. Ramsey, MD, PhD, ISPOR Marilyn Dix Smith Leadership Award Committee Chair, Member, Fred Hutchinson Cancer Research Center, and Professor, School of Pharmacy, School of Medicine, University of Washington, Seattle, WA, USA
AWARDEE: Karen Rascati, PhD, RPh bio
Eckerd/Turley Centennial Professor, University of Texas College of Pharmacy, Austin, TX, USA
9:00 AM - 10:30 AM
FIRST PLENARY SESSION: THE USE OF "BIG DATA" - WHERE ARE WE AND WHAT DOES THE FUTURE HOLD?
This session will focus on two methodological approaches to the analysis of big data: (1) Graph Analytics approaches which facilitate the linkage of datasets with much less investment in initial data modelling and (2) Machine Learning approaches-many of which are closely related to traditional statistical methods from health services research, epidemiology, and health econometrics. The session will consider how these different approaches deal with issues of data quality and data completeness and the implications for the confidence in the conclusions drawn from such analyses.
Moderator: Marcus Wilson, PharmD bio
President, HealthCore, Wilmington, DE, USA
Using Big Data in Health Care – Graph Databases and Graph Analytics Approaches
Speaker: David R. Holmes III, PhD bio
Collaborative Scientist, Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, MN, USA
Using Big Data in Health Care – Statistical Caution When Using Big Data – Linking Medical Records and Health Care Transactions
Speaker: William H. Crown, PhD bio
Chief Scientific Officer, Optum Labs, Cambridge, MA, USA
Comparison of Machine Learning & Traditional Outcomes Research Methods from a Researcher’s Perspective
Speaker: Lesley H. Curtis, PhD bio
Professor in Medicine, Duke University School of Medicine and Duke Clinical Research Institute, Durham, NC, USA
Discussion
10:30 AM - 11:00 AM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
11:00 AM - 12:00 PM
ISSUE PANELS - SESSION I
Clinical Outcomes Research Issues
11:00 AM - 12:00 PM
Room: Room 710b (7th Floor)

IP1: CROSS-FUNCTIONAL COLLABORATION ON CER - WHY CAN'T WE WORK TOGETHER?

Moderator:

Leona E. Markson, ScD, Executive Director, Comparative & Outcomes Evidence, Merck, West Point, PA, USA

Panelists:

Sebastian Schneeweiss, MD, ScD, Professor of Medicine and Epidemiology, Harvard Medical School, Boston, MA, USA

Robert Epstein, MD, MS, CEO & President, Epstein Health, LLC., Woodcliff Lake, NJ, USA

Lesley H. Curtis, PhD, Professor in Medicine, Duke University School of Medicine, and Duke Clinical Research Institute, Durham, NC, USA

Economic Outcomes Research Issues
11:00 AM - 12:00 PM
Room: Room 518abc (5th Floor)

IP2: DOES HEALTH ECONOMICS HAVE A ROLE IN THE NEW ERA OF PERSONALIZED MEDICINE?

Moderator:

Scott Ramsey, MD, PhD, Member, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Panelists:

Anirban Basu, MS, PhD, Professor, Health Services, University of Washington, Seattle, WA, USA

John Watkins, PharmD, MPH, BCPS, Pharmacy Manager, Formulary Development, Premera Blue Cross, Mountlake Terrace, WA, USA

David L. Veenstra, PharmD, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

Health Policy Development Using Outcomes Research Issues
11:00 AM - 12:00 PM
Room: Room 520cf (5th Floor)

IP3: WHAT IS THE BEST WAY TO USE MCDA IN HEALTH TECHNOLOGY APPRAISAL?

Moderator:

Nancy Devlin, PhD, Research Director, Office of Health Economics, London, UK

Panelists:

Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

Stuart Peacock, DPhil, Co-Director, Cancer Control Research, BC Cancer Agency, Canadian Centre for Applied Research in Cancer Control, Vancouver, BC, Canada

Josie Godfrey, MAs, Associate Director, Highly Specialised Technologies, National Institute for Health and Care Excellence (NICE), London, UK


11:00 AM - 12:00 PM
Room: Room 710a (7th Floor)

IP4: IS IT TIME FOR A NEW DRUG DEVELOPMENT PARADIGM?

Moderator:

Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK

Panelists:

Penny Mohr, MA, Senior Vice President, Program Development, Center for Medical Technology Policy, Baltimore, MD, USA

Matthew Rousculp, PhD, Senior Director, Comparative Effectiveness and Health Policy Research, GlaxoSmith Kline, Research Triangle Park, NC, USA

Robert McDonough, MD, JD, MPP, Head, Clinical Policy Research and Development, Aetna, Hartford, CT, USA

Use of Real World Data Issues
11:00 AM - 12:00 PM
Room: Room 519ab (5th Floor)

IP5: REAL-WORLD EVIDENCE: IS IT FIT FOR PURPOSE? AND IF SO, WHEN?

Moderator:

Jennifer S. Graff, PharmD, Director, Comparative Effectiveness Research, National Pharmaceutical Council, Washington, DC, USA

Panelists:

Raj Sabharwal, MPH, Senior Manager, AcademyHealth, Washington DC, USA

Steven Pearson, MD, MSc, FRCP, President, Institute for Clinical and Economic Review, Boston, MA, USA

Reed Tuckson, MD, FACP, Managing Director, Tuckson Health Connections, Edina, MN, USA

12:00 PM - 2:15 PM
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
12:15 PM - 1:15 PM
EDUCATIONAL SYMPOSIA
12:15 PM - 1:15 PM
Room: Room 710a (7th Floor)
PREDICTIVE ANALYTICS: PROVIDING NOVEL APPROACHES TO ENHANCE OUTCOMES RESEARCH LEVERAGING BIG AND COMPLEX DATA

(Sponsored by IMS Health)

12:15 PM - 1:15 PM
ISPOR STUDENT RESEARCH SHOWCASE
Room: Room 520be (5th Floor)

This session will feature four outcomes research studies conducted by ISPOR student members and presented at the ISPOR 19th Annual International Meeting. A brief summary of the research study and conclusions will be presented by each student author and the impact of the role of big data in health care decision making will be discussed.

Moderators: Ebere Onukwugha, PhD, Assistant Professor, University of Maryland, School of Pharmacy, Baltimore, MD, USA; Dennis Raisch, PhD, Professor, University of New Mexico, College of Pharmacy, Albuquerque, NM, USA; Zeba M. Khan PhD, RPh, Vice President, Strategic Market Access & Policy, Celgene Corporation, Summit, NJ, USA,

Speakers: Stephanie Choi, MPH, University of Toronto, Toronto, ON, Canada; Mabel Moreno, Esp, Stat, Instituto de Evaluacion Tecnologica en Salud - IETS, Bogota D.C., Colombia; Zenia Judith Ferreira, BA, Canadian Centre for Applied Research in Cancer Control, British Columbia Cancer Agency, Vancouver, BC, Canada; Richa Sinha, PhD, MPH,Health and Disability Research Institute, Boston University School of Public Health, Boston, MA, USA

1:15 PM - 2:15 PM
POSTER AUTHOR DISCUSSION HOUR - SESSION I
2:15 PM - 3:15 PM
RESEARCH PODIUM PRESENTATIONS - SESSION I

2:15 PM - 3:15 PM
Room: Room 710a (7th Floor)
USA AFFORDABLE HEALTH CARE ACT STUDIES

AH1

2:15 PM - 2:30 PM

PROJECTING THE USE OF INPATIENT AND EMERGENCY DEPARTMENT SERVICES AFTER THE AFFORDABLE CARE ACT MEDICAID EXPANSION

Pickens G1, Carls G2, Eibner C3, Jiang HJ4, Karaca Z4, Weiss A1, Wong H4
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Ann Arbor, MI, USA, 3RAND Corporation, Arlington, VA, USA, 4Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA

AH2

2:30 PM - 2:45 PM

ESTABLISHING BENCHMARKS TO UNDERSTAND HOSPITAL UTILIZATION FOLLOWING MEDICAID EXPANSION UNDER THE AFFORDABLE CARE ACT

Weiss A1, Carls G2, Jiang HJ3, Karaca Z3, Pickens G1, Wong H3
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Ann Arbor, MI, USA, 3Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA

AH3

2:45 PM - 3:00 PM

ADJUSTING BUDGET IMPACT MODEL BASED ON NEW CHANGES DUE TO AFFORDABLE CARE ACT

Aggarwal S1, Topaloglu H2, Kumar S3
1Novel Health Strategies, Bethesda, MD, USA, 2NOVEL Health Strategies, Chevy Chase, MD, USA, 3GLOBAL ACCESS Monitor, Bethesda, MD, USA

AH4

3:00 PM - 3:15 PM

WILL THE AFFORDABLE CARE ACT (ACA) IMPROVE RACIAL/ETHNIC DISPARITY OF EYE EXAMINATION AMONG U.S. WORKING-AGE POPULATION WITH DIABETES?

Shi Q1, Fonseca V1, Zhao Y2, Krousel-Wood M1, Luo Q1, Shi L1
1Tulane University, New Orleans, LA, USA, 2College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, USA

2:15 PM - 3:15 PM
Room: Room 518abc (5th Floor)
COMPARATIVE EFFECTIVENESS RESEARCH STUDIES

CE1

2:15 PM - 2:30 PM

COMPARATIVE EFFECTIVENESS OF SMOKING CESSATION MEDICATIONS TO ATTENUATE WEIGHT GAIN FOLLOWING CESSATION

Yang M1, Wang X1, Chen H1, Johnson ML1, Essien EJ1, Peters RJ2, Abughosh S1
1University of Houston, Houston, TX, USA, 2University of Texas Health Science Center at Houston, Houston, TX, USA

CE2

2:30 PM - 2:45 PM

DETERMINING COMPARATIVE EFFECTIVENESS BENCHMARKS FOR EMERGING TREATMENTS FOR HEPATITIS C VIRUS (HCV) INFECTION IN THE SINGLE ARM STUDY DESIGN SETTING

Broglio K1, Quintana M1, Daar ES2, Kalsekar A3, Yuan Y3, Detry M1, Lewis R2, Le TK4, Berry S1
1Berry Consultants, LLC, Austin, TX, USA, 2Los Angeles Biomedical Research, Torrance, CA, USA, 3Bristol-Myers Squibb, Princeton, NJ, USA, 4Bristol-Myers Squibb, Hopewell, NJ, USA

CE3

2:45 PM - 3:00 PM

COMPARATIVE EFFECTIVENESS OF SURGERY AND DRUG THERAPY IN NEWLY DIAGNOSED PATIENTS WITH CAROTID ARTERY STENOSIS

Mehta DA, McCombs J
University of Southern California, Los Angeles, CA, USA

CE4

3:00 PM - 3:15 PM

ASSESSMENT OF COMPARATIVE EFFECTIVENESS RESEARCH METHODS GUIDANCE DOCUMENTS

McConeghy R1, Heinrich K2, Gatto N3, Caffrey A1
1University of Rhode Island, Kingston, RI, USA, 2Columbia University, New York, NY, USA, 3Pfizer, Inc, New York, NY, USA

2:15 PM - 3:15 PM
Room: Room 519ab (5th Floor)
MEDICAL DEVICE & DIAGNOSTIC RESEARCH STUDIES

MD1

2:15 PM - 2:30 PM

THE IMPACT OF MEDICAL DEVICE USE ON HOSPITAL COSTS

Ferguson M, Kim M, Patel P, Stockwell B
Boston Scientific, Natick, MA, USA

MD2

2:30 PM - 2:45 PM

COST-UTILITY OF TRANSCATHETER AORTIC VALVE IMPLANTATION COMPARED WITH SURGICAL AORTIC VALVE REPLACEMENT IN HIGH-RISK PATIENTS WITH SEVERE AORTIC STENOSIS: A PROSPECTIVE OBSERVATIONAL STUDY

Ribera A1, Ferreira-González I1, Slof J2, Cascant P1, Abdul-Jawad O1, Marsal JR1, Serra V1, Garcia del Blanco B1, Tornos P1, Sureda C1, Falces C3, Andrea R3, Gutiérrez E4, del Valle R5, Mota P6, Goicolea J7, Permanyer G1, Garcia-Dorado D1
1Vall d'Hebron University Hospital, Barcelona, Spain, 2Universitat Autonoma de Barcelona, Bellaterra, Spain, 3Hospital Clínic i Provincial de Barcelona, Barcelona, Spain, 4Instituto de Investigación Sanitaria Gregorio Maranon, Universidad Complutense, Madrid, Spain, 5Hospital Central de Asturias, Oviedo, Spain, 6Hospital Clínico de Valladolid, Valladolid, Spain, 7Hospital Puerta de Hierro/Majadahonda, Madrid, Spain

MD3

2:45 PM - 3:00 PM

ASSESSING WHETHER “BIG DATA” SOLUTIONS PROVIDE VALUE FOR DIAGNOSTICS MANUFACTURERS

Hertz D, Gavaghan M, Garfield S
GfK Market Access, Wayland, MA, USA

MD4

3:00 PM - 3:15 PM

REAL-WORLD COST EFFECTIVENESS OF THE MITRACLIP FOR THE TREATMENT OF HIGH-RISK MITRAL REGURGITATION

Asgar AW1, Khairy P1, Bernard L2, Cameron HL2, Ducharme A1, Guertin M1, Bonan R1, L'Allier P1, Tardif J1, Cohen D3
1Montreal Heart Institute, Montreal, QC, Canada, 2Cornerstone Research Group, Burlington, ON, Canada, 3Saint Lukes Hospital, Kansas City, KS, USA

2:15 PM - 3:15 PM
Room: Room 520ad (5th Floor)
RESEARCH ON MODELING METHODS STUDIES

MO1

2:15 PM - 2:30 PM

A UNIFIED FRAMEWORK FOR CLASSIFICATION OF METHODS FOR BENEFIT-RISK ASSESSMENT

Najafzadeh M1, Schneeweiss S1, Choudhry NK1, Bykov K1, Kahler K2, Martin D2, Arcona S2, Rogers JR1, Gagne JJ1
1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

MO2

2:30 PM - 2:45 PM

BENEFITS FROM INCORPORATING NETWORK META-ANALYSIS WITHIN STRATIFIED COST-EFFECTIVENESS ANALYSIS

Coyle D1, Coyle K2, Cameron C1, Lee KM3, Kelly S1, Steiner S4, Wells G5
1University of Ottawa, Ottawa, ON, Canada, 2Brunel University, Uxbridge, ON, Canada, 3Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada, 4Medical University Vienna, Vienna, Austria, 5University of Ottawa Heart Institute, Ottawa, ON, Canada

MO3

2:45 PM - 3:00 PM

POPULATION HEALTH MODEL: PROJECTING HEALTH TRAJECTORY OF THE MASSACHUSETTS POPULATION

Olchanski N1, Zhong Y1, Winn A2, Saret CJ1, Cohen JT3
1Tufts Medical Center, Boston, MA, USA, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA

MO4

3:00 PM - 3:15 PM

AN EMPIRICAL COMPARISON OF A MARKOV COHORT MODEL AND A DISCRETE EVENT SIMULATION FOR COST-EFFECTIVENESS ANALYSIS IN ORTHOPAEDICS

Standfield LB, Comans T, Scuffham PA
Griffith University, Meadowbrook, Australia

2:15 PM - 3:15 PM
Room: Room 520cf (5th Floor)
PATIENT PREFERENCE STUDIES

PP1

2:15 PM - 2:30 PM

PREFERENCES FOR PROSTATE CANCER OUTCOMES: A COMPARISON OF PATIENT AND GENERAL POPULATION PERSPECTIVES

Gries KS1, Regier DA2, Ramsey SD3, Patrick DL1
1University of Washington, Seattle, WA, USA, 2BC Cancer Agency, Vancouver, BC, Canada, 3Fred Hutchinson Cancer Research Center, Seattle, WA, USA

PP2

2:30 PM - 2:45 PM

MAXIMUM DIFFERENCE SCALING: A NOVEL TECHNIQUE FOR DETERMINING PATIENT PREFERENCES

Stephenson JJ1, Kern DM2, Wu B2, Tunceli O2, Rodriguez A2, Horne LN3, Sackeyfio A4, Mackillop N4
1HealthCore Inc, Wilmington, DE, USA, 2HealthCore, Inc., Wilmington, DE, USA, 3AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA, 4AstraZeneca, Alderley Park, UK

PP3

2:45 PM - 3:00 PM

HOW CANADIANS VALUE RARE DISEASES GIVEN THEIR OPPORTUNITY COST?

Rizzardo S, Bansback N, Mitton C, Marra C, Lynd L
University of British Columbia, Vancouver, BC, Canada

PP4

3:00 PM - 3:15 PM

PATIENT PREFERENCES OF TREATMENTS AMONG WOMEN WITH METASTATIC BREAST CANCER: RESULTS FROM A CONJOINT ANALYSIS STUDY

DiBonaventura M1, Copher R2, Basurto E1, Faria C2, Lorenzo R1
1Kantar Health, New York, NY, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA

2:15 PM - 3:15 PM
Room: Room 520be (5th Floor)
TREATMENT PATTERNS STUDIES

TP1

WITHDRAWN

TP2

2:15 PM - 2:30 PM

TREATMENT PATTERNS AMONG ELDERLY STAGE IV BREAST CANCER PATIENTS TREATED WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-TARGETED THERAPY: AN ANALYSIS OF 2006-2010 US NATIONAL REGISTRY DATA

Lang K1, Hao Y2, Huang H1, Lin I1, Rogerio JW2, Menzin J1
1Boston Health Economics, Inc., Waltham, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

TP3

2:30 PM - 2:45 PM

LONGITUDINAL RESOURCE USE FOR LOW BACK PAIN IN COMMERCIALLY-INSURED PATIENTS IN THE UNITED STATES

Bresnahan BW1, Rundell S1, Beck SJ2, Hansen RN3, Jarvik JG1, Sullivan SD1, Flum D4, Alfonso-Cristancho R4
1University of Washington, Seattle, WA, USA, 2University of Washington, Department of Surgery, Seattle, WA, USA, 3School of Pharmacy, University of Washington, Seattle, WA, USA, 4Department of Surgery, University of Washington, Seattle, WA, USA

TP4

2:45 PM - 3:00 PM

DESCRIPTIVE ANALYSIS OF TREATMENT PATTERNS AND MORTALITY OF U.S. VETERAN PATIENTS WITH COLORECTAL CANCER

Seal BS1, Xie L2, Rietschel P3, Baser O4
1Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, 2STATinMED Research, Ann Arbor, MI, USA, 3Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA, 4STATinMED Research and The University of Michigan, Ann Arbor, MI, USA
3:15 PM - 3:45 PM
BREAK & EXHIBITS VIEWING
3:45 PM - 7:45 PM
RESEARCH POSTER PRESENTATIONS - SESSION II
3:45 PM - 4:45 PM
RESEARCH PODIUM PRESENTATIONS - SESSION II

3:45 PM - 4:45 PM
Room: Room 519ab (5th Floor)
RESEARCH ON DATABASE METHODS STUDIES

DB1

3:45 PM - 4:00 PM

A COMPARISON OF REGRESSION AND STATISTICAL LINKAGE ESTIMATORS OF BIAS IN RETROSPECTIVE DATABASE STUDIES

Crown W1, Chang J1, Olson M2, Kahler K3, Buzinec P4
1Optum Labs, Cambridge, MA, USA, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4OptumInsight, Eden Prairie, MN, USA

DB2

4:00 PM - 4:15 PM

CONDITIONS OF VALIDITY OF MEDICAL RECORDS FOR DRUG EXPOSURE ASSESSMENT IN PHARMACOEPIDEMIOLOGICAL RESEARCH

Grimaldi-Bensouda L1, Rossignol M1, Aubrun E1, Benichou J2, Abenhaim L3
1LA-SER, Paris, France, 2CHU de Rouen, INSERM U657, Rouen, France, 3LA-SER, London, UK

DB3

4:15 PM - 4:30 PM

A SPATIAL DISTRIBUTION OF ADULT OBESITY PREVALENCE IN DENVER COUNTY, COLORADO: AN EMPIRICAL BAYES APPROACH

Tabano DC1, Barrow JC1, Daley MF2
1Kaiser Permanente, Denver, CO, USA, 2Kaiser Permanente Institute for Health Research, Denver, CO, USA

DB4

4:30 PM - 4:45 PM

THE APPLICATION OF NATURAL LANGUAGE PROCESSING (NLP) TECHNOLOGY TO ENRICH ELECTRONIC MEDICAL RECORDS (EMRS) FOR OUTCOMES RESEARCH IN ONCOLOGY

Hirst C1, Hill J2, Khosla S1, Schweikert K2, Senerchia C2, Kitzmann K2, Zhang Q1
1AstraZeneca, Macclesfield, UK, 2Humedica, Boston, MA, USA

3:45 PM - 4:45 PM
Room: Room 518abc (5th Floor)
HEALTH CARE POLICY STUDIES

HC1

3:45 PM - 4:00 PM

CADTH RECOMMENDATIONS AS PREDICTORS FOR DRUG AVAILABILITY IN BRITISH COLUMBIA AND ONTARIO

Liden D, Jaksa A, Daniel K, Ho Y
Context Matters, Inc., New York, NY, USA

HC2

4:00 PM - 4:15 PM

THE IMPACT OF NICE'S END-OF-LIFE THRESHOLD ON PATIENT ACCESS TO NEW CANCER THERAPIES IN ENGLAND AND WALES

Stewart G, Eddowes L, Hamerslag L, Kusel J
Costello Medical Consulting Ltd., Cambridge, UK

HC3

4:15 PM - 4:30 PM

INCENTIVIZING VALUE IN MANAGED CARE DRUG FORMULARIES: DESIGN, IMPLEMENTATION, AND FIRST-YEAR OUTCOMES OF A VALUE-BASED FORMULARY

Watkins J1, Sullivan SD2, Yeung K3, Ramsey S4, Garrison L2, Wong E1, Murphy C1, Danielson D1, Veenstra DL3, Vogeler C1, Burke W5, McGee R1
1Premera Blue Cross, Mountlake Terrace, WA, USA, 2School of Pharmacy, University of Washington, Seattle, WA, USA, 3University of Washington, Seattle, WA, USA, 4Fred Hutchinson Cancer Research Center and Professor, Department of Medicine, University of Washington, Seattle, WA, USA, 5School of Medicine, University of Washington, Seattle, WA, USA

HC4

4:30 PM - 4:45 PM

THE POTENTIAL IMPACT OF RECOMMENDATIONS MADE THROUGH THE COMMON DRUG REVIEW PROGRAM AT THE CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH

Agarwal A1, Coyle D2, Lee KM1
1Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada

3:45 PM - 4:45 PM
Room: Room 710a (7th Floor)
HEALTH TECHNOLOGY ASSESSMENT STUDIES

HT1

3:45 PM - 4:00 PM

RECENT HEALTH TECHNOLOGY ASSESSMENT DECISIONS ACROSS THE GLOBE: A FOCUS ON ONCOLOGY

Clark RS, Zagadailov E, Bramley T
Xcenda, Palm Harbor, FL, USA

HT2

4:00 PM - 4:15 PM

ASSESSING THE VALUE OF TREATMENTS FOR RARE DISEASES USING AN MCDA-BASED APPROACH: METHODOLOGICAL AND ETHICAL FOUNDATIONS OF CRITERIA SELECTION AND FRAMEWORK DEVELOPMENT

Wagner M1, Khoury H1, Willet J2, Rindress D1, Goetghebeur M1
1LASER Analytica, Montreal, QC, Canada, 2LASER Analytica, New York, NY, USA

HT3

4:15 PM - 4:30 PM

IDENTIFYING RECENT TRENDS IN HEALTH TECHNOLOGY ASSESSMENTS FOR CROHN'S DISEASE

Mahendraratnam N, Inocencio TJ, Gaffney J, Agatep BC, Hughes KE
Avalere Health LLC, Washington, DC, USA

HT4

4:30 PM - 4:45 PM

COST-EFFECTIVENESS REVIEWS BY HTA AGENCIES: A COMPARISON OF FACTORS LEADING TO UNFAVOURABLE REVIEWS FOR ONCOLOGY AGENTS

Smith N, Beckerman R
CBPartners, New York, NY, USA

3:45 PM - 4:45 PM
Room: Room 520ad (5th Floor)
MEDICATION ADHERENCE STUDIES

MA1

3:45 PM - 4:00 PM

NON-ADHERENCE IS ASSOCIATED WITH POORER HEALTH OUTCOMES AMONG WOMEN CURRENTLY TREATED FOR BREAST CANCER WITH ORAL ENDOCRINE THERAPY

Goren A1, Geynisman DM2
1Kantar Health, New York, NY, USA, 2Fox Chase Cancer Center Temple Health, Philadelphia, PA, USA

MA2

4:00 PM - 4:15 PM

NON-ADHERENCE TO ANTIPLATELET THERAPY AFTER HOSPITALIZATION FOR ACUTE CORONARY SYNDROME (ACS) INCREASES READMISSIONS, MORTALITY, HEALTH CARE USE AND COSTS

Hill J1, Pokras SM1, Makin C1, Schabert VF1, Nelson M2, Foody J3
1IMS Health, Plymouth Meeting, PA, USA, 2IMS Health, Alexandria, VA, USA, 3Brigham and Women’s Hospital, Boston, MA, USA

MA3

4:15 PM - 4:30 PM

ADHERENCE AND PATIENT REPORTED OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING BIOLOGIC MEDICATIONS: ANALYSIS OF SPECIALTY PHARMACY PROGRAM DATA

Olvey EL1, Crowe M2, Chandanais R2, Nolan R2, Rice G2
1NucleusX Market Access, Atlanta, GA, USA, 2Diplomat Pharmacy, Flint, MI, USA

MA4

4:30 PM - 4:45 PM

SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF MEDICATION ADHERENCE WITH ONCE WEEKLY VERSUS ONCE DAILY THERAPY IN PATIENTS WITH OSTEOPOROSIS

Iglay K, Joshi K, Cao X, Mavros P, Tunceli K
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA

3:45 PM - 4:45 PM
Room: Room 520be (5th Floor)
RISK MANAGEMENT STUDIES

RI1

3:45 PM - 4:00 PM

PREDICTING THE RISK OF CLOSTRIDIUM DIFFICILE INFECTION UPON ADMISSION: A RISK SCORE TO IDENTIFY PATIENTS FOR PHARMACIST ANTIBIOTIC REVIEW AND EDUCATION

Smith DH, Kuntz JL, Petrik AF, Yang X, Thorp ML, Spindel SJ, Barton T, Barton K, Labreche M, Johnson ES
Kaiser Permanente Northwest, Portland, OR, USA

RI2

4:00 PM - 4:15 PM

WARFARIN DISCONTINUATION AND STROKE RISK AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

Wang J1, Qiao Y1, Spivey CA1, Liu X2, Phatak H3, Mardekian J4, Claflin AB4, Kachroo S3, Abdulsatter Y4, Parker RB1
1The University of Tennessee College of Pharmacy, Memphis, TN, USA, 2University of Tennessee, College of Pharmacy, New York, NY, USA, 3Bristol-Myers Squibb Company, Princeton, NJ, USA, 4Pfizer, Inc., New York, NY, USA

RI3

4:15 PM - 4:30 PM

DISPARITY IN HIGH RISK MEDICATION USE BETWEEN DUAL AND NON-DUAL ELIGIBLE MEDICARE ADVANTAGE BENEFICIARIES: A DECOMPOSITION ANALYSIS

Pulungan Z, Parente A, Mehta S, Jones B, Teigland C
Inovalon Inc., Bowie, MD, USA

RI4

4:30 PM - 4:45 PM

RISK FACTORS ASSOCIATED WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) BACTEREMIA IN THE UNITED STATES

Pawar AM, Willey CJ, Caffrey AR
University of Rhode Island, Kingston, RI, USA

3:45 PM - 4:45 PM
Room: Room 520cf (5th Floor)
UTILITY MEASUREMENT STUDIES

UT1

3:45 PM - 4:00 PM

EQ-5D: WHICH DIMENSION MATTERS MOST AMONG DIABETES PATIENTS

Dierick K1, Mcbride M2, Love T2, Dean C3, Pike I3, Herterich R4
1GfK Disease Atlas, Brussels, Belgium, 2GfK USA, New York, NY, USA, 3GfK NOP, London, UK, 4GfK, Nürnberg, Germany

UT2

4:00 PM - 4:15 PM

HEALTH STATE UTILITIES ASSOCIATED WITH ATTRIBUTES OF TREATMENTS FOR HEPATITIS C

Matza LS1, Sapra S2, Kalsekar A2, Dillon JF3, Davies E4, Devine MK1, Jordan J1, Landrian A1, Feeny DH5
1Evidera, Bethesda, MD, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3University of Dundee, Dundee, UK, 4Evidera, London, UK, 5University of Alberta, Portland, OR, USA

UT3

4:15 PM - 4:30 PM

ASSESSING FACTORS ASSOCIATED WITH SELF-REPORTED HEALTH STATUS IN THE UNITED STATES USING A STRUCTURAL EQUATION MODEL

Zhao Y, Gu NY
University of New Mexico, Albuquerque, NM, USA

UT4

4:30 PM - 4:45 PM

DEVELOPMENT AND VALIDATION OF AN APPROACH TO INTERPRET COMPUTERIZED ADAPTIVE TEST SCORES FOR ASSESSING PATIENT OUTCOMES

Sinha R1, Slavin MD1, Ni P1, Houlihan B1, Skeels SE2, Zazula J1, Jette A1
1Boston University School of Public Health, Boston, MA, USA, 2Tufts University, Medford, MA, USA
5:00 PM - 6:00 PM
WORKSHOPS - SESSION I
Clinical Outcomes Research
5:00 PM - 6:00 PM
Room: Room 710b (7th Floor)
W1: CHANGING THE DRUG DEVELOPMENT PARADIGM
Discussion Leaders:

Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK

Penny Mohr, MA, Senior Vice President, Program Development, Center for Medical Technology Policy, Baltimore, MD, USA

Donna Messner, PhD, Research Director, Center for Medical Technology Policy, Baltimore, MD, USA

Economic Outcomes Research
5:00 PM - 6:00 PM
Room: Room 520ad (5th Floor)
W2: A NEW VALIDATION-ASSESSMENT TOOL FOR HEALTH-ECONOMIC DECISION MODELS
Discussion Leaders:

Pepijn Vemer, MSc, Researcher, Epidemiology, UMC Groningen, Groningen, The Netherlands

George Van Voorn, PhD, Senior Researcher, Biometrics, Wageningen University & Research, Wageningen, The Netherlands

Isaac Corro Ramos, PhD, Senior Researcher, Institute of Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The Netherlands

Josephine A. Mauskopf, PhD, MHA, MA, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA

Health Care Policy Development Using Outcomes Research
5:00 PM - 6:00 PM
Room: Room 518abc (5th Floor)
W3: USE OF NETWORK META-ANALYSIS IN DIFFERENT SETTINGS: METHODOLOGICAL AND POLICY CONSIDERATIONS
Discussion Leaders:

Huseyin Naci, PhD, MHS, Fellow in Pharmaceutical Policy Research, Department of Population Medicine, Harvard Medical School, Boston, MA, USA

James D Chambers, PhD, MPharm, MSc, Assistant Professor, The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

Jeroen P Jansen, PhD, Director, Redwood Outcomes, San Francisco, CA, USA


5:00 PM - 6:00 PM
Room: Room 519ab (5th Floor)
W4: MODELLING ALCHEMY: THE IMPACT OF UNORTHODOX TRIAL DESIGN ON HEALTH TECHNOLOGY APPRAISAL STRATEGY
Discussion Leaders:

Rachel Beckerman, PhD, Principal, Value Demonstration, CBPartners, New York, NY, USA

Meghan Gallagher, Director, Global Health Economics and Outcomes Research, Oncology, Sanofi, Cambridge, MA, USA

Anthony Hatswell, MSc, Principle Consulting Economist, BresMed, Sheffield, UK

Marc Bardou, MD, PhD, Gastroenterologist, Centre Hospitalier Universitaire Le Bocage, Dijon, France

Patient-Reported Outcomes & Patient Preference Research
5:00 PM - 6:00 PM
Room: Room 710a (7th Floor)
W5: REGULATORY QUALIFICATION OF CLINICAL OUTCOME ASSESSMENT TOOLS FOR DOCUMENTING TREATMENT BENEFIT IN CLINICAL TRIALS: CORE ISSUES
Discussion Leaders:

Stephen Joel Coons, PhD, Executive Director, Patient-Reported Outcome (PRO) Consortium, Critical Path Institute, Tucson, AZ, USA

Ari Gnanasakthy, MSc, Head, Patient Reported Outcomes, Novartis Pharmaceuticals, East Hanover, NJ, USA

Ashley Slagle, PhD, MS, Endpoints Reviewer, SEALD, ONDIO, CDER, U.S. Food & Drug Administration (FDA), Silver Spring, MD, USA

Elisabeth Piault, PharmD, MA, Senior Patient Reported Outcomes Scientist, Genentech, San Francisco, CA, USA

Use of Real World Data
5:00 PM - 6:00 PM
Room: Room 520be (5th Floor)
W6: A REALISTIC APPROACH TO WORKING WITH ONCOLOGY ELECTRONIC MEDICAL RECORD (EMR) DATA IN OUTCOMES RESEARCH
Discussion Leaders:

Kathy Foley, PhD, Senior Director, Strategic Consulting, Life Sciences, Truven Health Analytics, Cambridge, MA, USA

Katherine B Winfree, PhD, MPH, Senior Research Scientist, Eli Lilly and Company, Indianapolis, IN, USA

Claudio Faria, PharmD, MPH, Director, Health Economics & Outcomes Research, Eisai, Inc., Woodcliff Lake, NJ, USA

Leigh G. Hansen, MS, MBA, Vice President, Market Planning & Strategy - Life Sciences, Truven Health Analytics, Northwood, NH, USA


5:00 PM - 6:00 PM
Room: Room 520cf (5th Floor)
W7: ESTIMATING HETEROGENEITY OF TREATMENT EFFECTS USING DECOMPOSITION TECHNIQUES WITH OBSERVATIONAL DATA: FROM IVORY TOWER TO THE REAL WORLD
Discussion Leaders:

Lee Brekke, PhD, Director, Health Economics and Outcomes Research, OptumInsight, Eden Prairie, MN, USA

Michael Grabner, PhD, Research Manager, Health Economics & Outcomes Research, HealthCore, Inc., Wilmington, DE, USA

Wenhui Wei, PhD, MS, MBA, Director, Evidence Based Medicine, Sanofi U.S., Bridgewater, NJ, USA

6:00 PM - 7:45 PM
EXHIBITORS' OPEN HOUSE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II
6:00 PM - 6:30 PM
ISPOR ANNUAL BUSINESS MEETING
Room: 525ab (5th Floor)
Call to order: William H. Crown, PhD, ISPOR President (2012-2014)
Executive Director’s Report: Marilyn Dix Smith, RPh, PhD, ISPOR Executive Director
Treasurer’s Report: Zeba M. Khan, RPh, PhD, ISPOR Treasurer
Audit Report: Adrian Griffin, MSc
Value in Health Co-Editors-in-Chief Report: C. Daniel Mullins, PhD and Michael Drummond, PhD
Value in Health Regional Issues Co-Editor-in-Chief Report: Bong-min Yang, PhD, Federico Augustovski, MD, MSc, PhD, and Dan Greenberg, PhD
ISPOR CONNECTIONS Editor-in-Chief Report: David Thompson, PhD
Member Open Discussion: ISPOR Members
New Business: William H. Crown, PhD
6:15 PM - 7:15 PM
ISPOR FORUMS - SESSION I

6:15 PM - 7:15 PM
Room: Room 518abc (5th Floor)
ISPOR CLINICIAN REPORTED OUTCOMES GOOD MEASUREMENT PRACTICES
Moderator:

John H. Powers, III, MD, FACP, FIDSA, Senior Medical Scientist, SAIC in Support to Collaborative Clinical Research Branch (CCRB), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) and Associate Clinical Professor of Medicine, George Washington University School of Medicine, Washington, DC, USA

Speakers:

Laurie B. Burke, RPh, MPH, Former Associate Director for Study Endpoints and Labeling Office of New Drugs, CDER, U.S. Food & Drug Administration (FDA) and Founder, LORA Group, LLC, Royal Oak, MD, USA

Patrick Marquis, MD, MBA, President, Twolegs Consulting, Newton, MA, USA

Ashley Slagle, PhD, MS, Endpoints Reviewer, SEALD, ONDIO, CDER, U.S. Food & Drug Administration (FDA), Silver Spring, MD, USA


6:15 PM - 7:15 PM
Room: Room 710b (7th Floor)
SIMULATION MODELING APPLICATIONS IN HEALTH CARE DELIVERY RESEARCH — EMERGING GOOD PRACTICES
Moderator:

Deborah A. Marshall, PhD, Canada Research Chair, Health Services and Systems Research and Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada

Speakers:

William Crown, PhD, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA

Maarten J. IJzerman, PhD, Professor of Clinical Epidemiology & Health Technology Assessment (HTA) and Head, Department of Health Technology & Services Research, MIRA Institute for Biomedical Technology & Technical Medicine, University of Twente, Enschede, The Netherlands


6:15 PM - 7:15 PM
Room: Room 710a (7th Floor)
RARE DISEASES: CHALLENGES IN ASSESSMENT AND APPRAISAL OF DIAGNOSTICS & TREATMENTS
Moderator:

Chris L. Pashos, PhD, Vice President, Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc., Cambridge, MA, USA

Speakers:

Mondher Toumi, MD, MSc, PhD, Professor & Chair of Decision Sciences, Department of Public Health and Market Access, University Claude Bernard Lyon I, Paris, France

Christopher Blanchette, PhD, MBA, Associate Dean for Research, College of Health and Human Services, University of North Carolina at Charlotte, Charlotte, NC, USA

Daria Korchagina, MSc, Pricing & Market Access Analyst, Creativ-Ceutical, Paris, France


6:15 PM - 7:15 PM
Room: Room 519ab (5th Floor)
WHAT IS VALUE IN HEALTH DOING FOR ITS AUTHORS?
Moderator:

Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK bio

Speakers:

C. Daniel Mullins, PhD, Co-Editor-in-Chief, Value in Health and Professor, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA


6:15 PM - 7:15 PM
Room: Room 520ad (5th Floor)
THE EVOLUTION OF HEALTH TECHNOLOGY ASSESSMENT IN LATIN AMERICA: ARE WE THERE YET?
Moderator:

Gabriela Tannus, MBA, MSc, 2012-2014 ISPOR Latin America Consortium Executive Committee Chair and Owner & Health Economics Director, Axia.Bio, Sao Paulo, Brazil

Speakers:

Federico Augustovski, MD, MSc, PhD, Director, Economic Evaluations & HTA Department, Institute for Clinical Effectiveness and Health Policy (IECS), Professor of Public Health, University of Buenos Aires and Staff Physician, Family and Community Medicine Division, Italian Hospital of Buenos Aires, Buenos Aires, Argentina

Manuel Antonio Espinoza, MD, MSc, PhD, Assistant Professor, Faculty of Medicine, Department of Public Health, Catholic University of Chile and Scientific Coordinator, National Centre for Pharmacoeconomics, Institute of Public Health of Chile, Santiago, Chile

Rosa Maria Galindo-Suarez, MHE, Prioritization Deputy General Director, Ministry of Health, Mexico City, Mexico


6:15 PM - 7:15 PM
Room: Room 520be (5th Floor)
CAPACITY BUILDING IN PHARMACOECONOMICS IN THE ARABIC-SPEAKING COUNTRIES: CHALLENGES & OPPORTUNITIES IN EDUCATION AND TRAINING
Moderator:

Ola Ghaleb Al Ahdab, PhD, President, ISPOR United Arab Emirates Chapter and Pharmaceutical Advisor & Project Manager, Registration and Drug Control Department, Ministry of Health, Abu Dhabi, United Arab Emirates

Speakers:

Daoud Al-Badriyeh, BPharm, PhD, President, ISPOR Qatar Chapter and Assistant Professor of Pharmacoeconomics, College of Pharmacy, Qatar University, Doha, Qatar

Abdulaziz H. Al-Saggabi, MSc, PharmD, President of ISPOR Saudi Arabia Regional Chapter, Drug Policy & Economics Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia

Ibrahim Al-Abbadi, PhD, MBA, BPharm, President, ISPOR Jordan Chapter and Dean, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan

Gihan Hamdy Elsisi, RPh, MSc, Head of Pharmacoeconomic Unit and Part-time Lecturer of Pharmacoeconomics, Central Administration for Pharmaceutical Affairs, Ministry of Health, Faculty of Pharmacy Helwan University, Cairo, Egypt


6:15 PM - 7:15 PM
Room: Room 520cf (5th Floor)
DEFINING AND INCORPORATING BIG DATA IN HEALTH ECONOMICS AND OUTCOMES RESEARCH TO INFORM DECISIONS IN HEALTH CARE: IMPLICATIONS FOR CLINICAL PRACTICE, GOVERNMENT POLICY, AND STUDENTS' CAREER PATHS
Moderator:

Zeba M. Khan, RPh, PhD, ISPOR Student Network Advisor and Vice President, Strategic Market Access & Policy, Celgene Corporation, Summit, NJ, USA

Amanda Harrington, MS, ISPOR Student Network Chair and Graduate Research Assistant, University of Arizona, Tucson, AZ, USA

Speakers:

Abraham G. Hartzema, MSPH, PhD, FISPE, Professor and Eminent Scholar, Perry A. Foote Chair in Health Outcomes Research, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA

Wenhui Wei, PhD, MS, MBA, Director, Evidence Based Medicine, Medical Affairs, Sanofi US, Bridgewater, NJ, USA

Marcus Wilson, PharmD, President, HealthCore, Wilimington, DE, USA

6:45 PM - 7:45 PM
POSTER AUTHOR DISCUSSION HOUR - SESSION II
7:15 PM - 8:45 PM
ISPOR ARABIC NETWORK & AFRICA NETWORK JOINT RECEPTION
Room: 522b (5th Floor)
All attendees interested in the ISPOR Arabic & Africa Networks are welcome to attend

7:15 PM - 8:45 PM
ISPOR ASIA CONSORTIUM RECEPTION
Room: 524a (5th Floor)
All attendees interested in the ISPOR Asia Consortium are welcome to attend

7:15 PM - 8:45 PM
ISPOR LATIN AMERICA CONSORTIUM RECEPTION
Room: 524c (5th Floor)
All attendees interested in the ISPOR Latin America Consortium are welcome to attend

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2016 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.